RESIDENTIAL SCHOOL ON MEDICINAL CHEMISTRY:
Biology and Chemistry of Drug Discovery
Drew University, Madison, New Jersey
June 13 – 17, 2011

LECTURES
“Strategic Issues in Drug Discovery”
“Enzyme Inhibition”
“Receptor Binding Assays”
“Hit-to-Lead Process in Drug Discovery”
“Lead Discovery & Modification (2)”
“Fragment-based Drug Design”
“Structure-based Drug Design”
“Drug-like Properties in Drug Discovery”
“Plasma Protein Binding”
“Monoclonal Antibodies”
“Preclinical Toxicology”
“G-Protein-Coupled Receptors”
“Kinase Inhibitors”
“Drugs Affecting ION Channels”
“Clinical Development”

FACULTY
Magid Abou-Gharbia, Ph.D., Temple University
Eugene Cordes, Ph.D., Vertex Pharmaceuticals
Christopher Haber, Ph.D., Pfizer
Craig Lindsley, Ph.D., Vanderbilt University
Richard Silverman, Ph.D., Northwestern University
Miles Congreve, Ph.D., Heptares Therapeutics
Jonathan Greer, Ph.D., Abbott Laboratories
Edward Kerns, Ph.D., Pfizer
George Trainor, Ph.D., Bristol-Myers Squibb
Tina Meng, Ph.D., Amgen
James MacDonald, Ph.D., Chrysalis Pharma
Jeff Reagan, Ph.D., Amgen
William Windsor, Ph.D., Merck
David J. Triggle, Ph.D., SUNY Buffalo
James McLeod, M.D., Merck

SEMINARS
“Drug Metabolism for Medicinal Chemists and Biologists”
“Molecular Modeling”
“Pharmacokinetics and ADME”

FACULTY
John Erve, Ph.D., Novartis
Jonathan Greer, Ph.D., Abbott Laboratories
Cheryl Zimmerman, Ph.D., Univ. of Minnesota

CASE HISTORIES
“MK-4305”
“Eltrombopag”
“Pazopanib”
“Saxagliptin”
“Raltagravir”

FACULTY
Paul Coleman, Ph.D., Merck
Kevin Duffy, Ph.D., GlaxoSmithKline
Philip Harris, Ph.D., GlaxoSmithKline
Jeffrey Robl, Ph.D., Bristol-Myers Squibb
John Wai, Ph.D., Merck